In RCC, low expression of METTL14 (Zhang et al., 2021a; Liu et al., 2022d), EIF3A (Zhang et al., 2021b), FTO (Zhuang et al., 2019), ALKBH5 (Strick et al., 2020), YTHDF2 (Mu et al., 2020; Su et al., 2021; Xu et al., 2022a), ZC3H13, and KIAA1429 (Wang et al., 2020) were associated with poor prognosis, while low levels of METTL3 (Xu et al., 2021a; Zhu et al., 2022), WTAP (He et al., 2021), IGF2BPs (Ying et al., 2021), YTHDC1, YTHDF1, and YTHDF3 (Von Hagen et al., 2021) were associated with longer overall survival of patients. This evidence concerns the gene METTL14 and renal cell carcinoma.